Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in

Topical ruxolitinib for HS is a tough ask: HS is a deep follicular/inflammatory disease where topicals have historically underperformed vs systemics (adalimumab, secukinumab, bimekizumab). HiSCR75 is a stringent bar (vs standard HiSCR50) rarely hit even by biologics. No strong Phase 2 signal publicly supports topical JAK penetration into deep nodules/tunnels. Vehicle response in HS trials can be meaningful, compressing delta. Safety likely fine, but efficacy on HiSCR75 at wk16 is the key risk.

Vehicle-controlled Phase 3 design and sponsor experience support execution, but Week 16 HiSCR75 is stringent for a topical therapy in a deep, heterogeneous disease. Enrollment risk is reduced, yet no sample size, powering assumptions, or prior efficacy signal is provided, leaving substantial efficacy risk.

Phase 3, placebo-controlled design and an objective Week-16 HiSCR75 endpoint support a credible test, but HiSCR75 is a demanding response threshold in heterogeneous hidradenitis suppurativa. Topical delivery may limit effect in deeper inflammatory disease, and no prior efficacy, sample-size, or operational details are provided.

Phase 3 status, a vehicle-controlled design, and a clear Week 16 HiSCR75 endpoint support a credible efficacy test. Active-not-recruiting status lowers execution uncertainty. However, the fields provide no sample size, prior efficacy signal, patient severity mix, or dropout assumptions, so the probability remains only moderately above 50%.

Phase 3, active not recruiting, HiSCR75 (stringent 75% AN reduction, no abscess/drainage increase) at wk 16 vs vehicle; no sample size, powering, or prior HS data in fields; HS indication historically difficult with variable placebo responses and high bar for 75% response.

Phase 2 showed a significant but modest reduction in mean AN count (-3.61 vs -2.42 vehicle; P=0.0215) in mild-to-moderate HS. However, the Phase 3 primary endpoint is HiSCR75, a stringent 75% reduction threshold. Deep HS lesions are difficult to treat topically, and high vehicle responses common in topical trials may compress the effect size, posing substantial risk.

Ruxolitinib cream previously failed Phase 3 in HS (TRuE-HS1/2). Topical JAK unlikely to penetrate deep tunnels/abscesses. HiSCR75 is a stringent endpoint. No design changes evident. Base rate for Phase 3 success after prior failure is low, ~25%.

TRuE-HS2 is a replicate Phase 3 of ruxolitinib cream in HS using HiSCR75 at Week 16. The twin trial TRuE-HS1 reportedly met its primary endpoint, strongly boosting odds for this replicate given identical design, dosing, and population. JAK inhibition has solid biologic rationale in HS. Key risk is historically high and variable placebo response in HS dermatology trials, which can cause replicate failures even after a positive first trial.

TRuE-HS2 is the second pivotal Phase 3 trial for Incyte's ruxolitinib cream in HS. Given the positive results from the companion TRuE-HS1 trial and the strong mechanistic rationale for JAK inhibition in HS inflammation, the probability of replicating success is high. The HiSCR75 endpoint is standard and well-validated. Operational execution appears stable with Active Not Recruiting status.

Phase‑3 trial, active not recruiting, no efficacy data yet. Primary endpoint HiSCR75 at week 16 is stringent for hidradenitis suppurativa; similar trials have modest success (~30‑40%). Safety profile of ruxolitinib cream is promising but unproven in this indication, leading to modest intrinsic chance of a positive result.

Ruxolitinib cream is a topical JAK inhibitor in HS, a challenging indication with no approved topical therapies. Phase 3 TRuE-HS2 uses HiSCR75 at Week 16, a stringent endpoint. Prior oral JAK data in HS (e.g., upadacitinib) showed efficacy but topical penetration in deep HS lesions is questionable. Active-not-recruiting status with 129 days to completion suggests data readout approaching. No prior Phase 2 data for this cream in HS publicly disclosed, increasing uncertainty. Vehicle-controlled design with subjective endpoint creates execution risk.

HS is a notoriously difficult indication with high trial failure rates. Topical ruxolitinib cream faces pharmacological challenges reaching deep HS lesions (abscesses, tunnels). HiSCR75 is a stringent endpoint (75% reduction), higher than the more commonly used HiSCR50 in HS trials, raising risk. Incyte's Phase 2 data showed only mixed signals. TRuE-HS1 outcome not yet known as read-through. Active not recruiting with 86 days to primary completion. Estimating ~30% probability of positive result.